Key result
For patients with true resistant hypertension uncontrolled by optimal triple therapy, spironolactone is recommended as the fourth medication, alongside emerging options like renal denervation.
Why the study?
Uncontrolled hypertension is the leading global mortality risk factor, and some patients do not respond adequately to three or even five or more antihypertensive agents.
What are the recommended fourth-line and subsequent treatment options for patients with true resistant hypertension?
What are the recommended fourth-line and subsequent treatment options for patients with true resistant hypertension?
For true resistant hypertension, spironolactone remains the preferred fourth-line agent, with novel pharmacological therapies and renal denervation offering additional avenues for control.
INTRODUCTION: Uncontrolled hypertension is the leading risk factor for global mortality. Most hypertensive patients can be controlled with standard medication combinations, but some may not respond adequately to ≥3 or even to ≥5 antihypertensive agents. AREAS COVERED: In this review, we summarize the recent literature on difficult-to-treat hypertension identified by a Medline search, and we discuss the options for fourth line and subsequent therapy. EXPERT OPINION: It is essential to confirm resistant hypertension with out-of-office blood pressure measurements and to consider lifestyle factors, adherence to medication and secondary causes of hypertension. When true resistant hypertension is confirmed and blood pressure is not controlled with an optimal triple combination, preferably as a fixed dose combination tablet, spironolactone is usually recommended as the fourth medication. Comorbid conditions should be treated as appropriate with sodium-glucose-cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, sacubitril-valsartan or finerenone. Renal denervation appears to be a useful addition to overcome some of the problems of medication adherence. The endothelin antagonist aprocitentan may be a final option in some countries. Of the drugs in development, the RNA based therapeutics that inhibit angiotensinogen synthesis appear to be some of the most promising.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2024) conducted a review in Uncontrolled hypertension. Fourth-line and subsequent antihypertensive therapies was evaluated. For patients with true resistant hypertension uncontrolled by optimal triple therapy, spironolactone is recommended as the fourth medication, alongside emerging options like renal denervation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: